Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)

The summary for the Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed): The goal of this Funding Opportunity Announcement (FOA) is to establish a Data Analysis and Coordination Center (DACC) that will be part of a collaborative initiative to advance the application of multi-omic technologies to study health and disease in diverse populations. Together with the Disease Study Sites (RFA-HG-22-008) and the Omics Production Center(s) (RFA-HG-22-009), the DACC will leverage clinical conditions where multi-omic approaches are expected to be most informative to: 1) explore the use of multi-omics, integrated with phenotypic and environmental exposure data, including social determinants of health (SDOH), to detect and assess molecular profiles associated with healthy and disease states; 2) develop generalizable data harmonization, integration, and analysis methods, as well as best practices and standards for the optimal application of multi-omics; and 3) create a multi-dimensional dataset that is available to the research community. The DACC will be primarily responsible for coordinating Consortium logistics, outreach, and dissemination of findings; for managing and securing Consortium data; for creating the multi-dimensional dataset; and for coordinating and contributing to consortium-wide protocol development, data analysis, and methods development efforts. While this program may provide some insights into disease etiology, its primary goal is to validate and enhance generalizable multi-omic approaches to identify meaningful biological changes related to health and disease.

Federal Grant Title:	Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Environment Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HG-22-010
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.113, 93.172, 93.396, 93.399
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 18th, 2022
Original Application Deadline:	November 18th, 2022
Posted Date:	September 7th, 2022
Creation Date:	September 7th, 2022
Archive Date:	December 24th, 2022
Total Program Funding:
Maximum Federal Grant Award:	$950,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	September 7th, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-010.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed); • Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic ...; • Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical...; • Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical...; • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed); • Outstanding New Environmental Scientist Award (ONES); • Environmental Health Sciences Core Center Grants; • Leiomyomata Uteri: Basic Science and Translational Research
More Grants from the National Institutes of Health: • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...; • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...